Description:
Cagrilintide is a long-acting amylin analog peptide under investigation for its potent effects on weight management. Studies have demonstrated its efficacy in reducing body weight, both as a standalone therapy and in combination with GLP-1 receptor agonists.
Research Application (SubQ, once weekly):
Week 1–4: 0.3 mg
Week 5–8: 0.6 mg
Week 9–12: 1.2 mg
Week 13+: 2.4–4.5 mg
Research Highlights:
Weight reduction up to 10.8% as monotherapy
Enhanced weight loss when combined with Semaglutide (CagriSema)
Modest improvements in glycemic control parameters
Availability:
Purity: ≥99%
Form: Lyophilized powder for reconstitution
Disclaimer:
The statements made on this website have not been evaluated by the US Food and Drug Administration. These are not findings from Raina's Summit, but instead publicly available studies. This product is for research purposes only.
Cagrilintide (5mg-10mg)
C₁₉₄H₃₁₂N₅₄O₅₉S₂
At Raina's Summit, we are committed to providing research compounds of the highest standard—we perform quality batch testing to verify each product meets a minimum purity of 99% or we guarantee your money back.